Stoke Therapeutics, Inc. Actuals & Estimates (DUS:0GT)
This article provides key financial data and analyst estimates for Stoke Therapeutics, Inc. (0GT) on the Dusseldorf Stock Exchange. It covers stock forecasts, historical price performance, earnings reports, revenue, net income, EBITDA, and employee numbers, along with details on upcoming earnings dates.
STOK (NASDAQ) lists 7,228 RSUs and reports two 10b5-1 sales
Stoke Therapeutics, Inc. (STOK) filed a Form 144 notice disclosing the proposed sale of 7,228 restricted stock units (RSUs) dated March 15, 2026. The filing also detailed two recent 10b5-1 sales executed by Baruch S. Ticho, involving 1,795 shares for $54,891.10 on June 1, 2026, and 2,243 shares for $73,547.97 on May 1, 2026. These transactions represent administrative disclosures of planned or completed insider stock transactions.
Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
Stoke Therapeutics has completed enrollment of 162 patients in its Phase 3 EMPEROR study of zorevunersen, an investigational medicine for Dravet syndrome. The company plans to initiate a rolling New Drug Application (NDA) submission to the U.S. FDA in Q1 2027, with Phase 3 data expected in Q3 2027. Zorevunersen aims to treat the underlying genetic cause of Dravet syndrome by increasing NaV1.1 protein production and has been granted several expedited designations.
Stoke completes Phase 3 enrollment for Dravet drug study
Stoke Therapeutics has finished enrolling 162 patients in its Phase 3 EMPEROR study for zorevunersen, a potential treatment for Dravet syndrome. The company plans to initiate a rolling FDA New Drug Application submission in Q1 2027, with data from the study expected in Q3 2027. Zorevunersen aims to be a disease-modifying RNA medicine, and the rapid enrollment highlights the severity of Dravet syndrome.
Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
Stoke Therapeutics has completed enrollment of 162 patients in the Phase 3 EMPEROR study for zorevunersen, an investigational medicine for Dravet syndrome. The company plans to initiate a rolling U.S. New Drug Application submission to the FDA in the first quarter of 2027, with Phase 3 data expected in the third quarter of 2027. Zorevunersen aims to be a first-in-class disease-modifying treatment for Dravet syndrome, focusing on increasing functional NaV1.1 protein production.
Stoke Therapeutics completes enrollment of 162 patients in Phase 3 EMPEROR; Q3 2027 readout, rolling NDA in 2027
Stoke Therapeutics has completed enrollment of 162 patients for the primary analysis population in its Phase 3 EMPEROR study of zorevunersen, with approximately 50 patients reaching the 28-week primary endpoint. The company anticipates a Phase 3 data readout in Q3 2027 and plans to initiate a rolling U.S. NDA submission in Q1 2027, completing it in H2 2027. An additional ~30-patient cohort in Europe is still enrolling, but these patients will not be included in the U.S. NDA.
Stoke Therapeutics (NASDAQ: STOK) completes Phase 3 Dravet trial enrollment, targets 2027 NDA
Stoke Therapeutics has completed enrollment of 162 patients for its pivotal Phase 3 EMPEROR study of zorevunersen, a potential treatment for Dravet syndrome. The company anticipates a Phase 3 data readout in Q3 2027 and plans to initiate a rolling U.S. New Drug Application (NDA) submission in Q1 2027, aiming for completion in the second half of 2027. Zorevunersen holds several special designations, including Breakthrough Therapy, and is being developed in collaboration with Biogen.
Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
Stoke Therapeutics has completed enrollment of 162 patients in its Phase 3 EMPEROR study for zorevunersen, an investigational medicine for Dravet syndrome. The company plans to initiate a rolling U.S. NDA submission to the FDA in Q1 2027, with Phase 3 data expected in Q3 2027 to complete the submission. Zorevunersen aims to be a first-in-class disease-modifying treatment for Dravet syndrome, with potential FDA approval and U.S. launch by early 2028.
Stoke Therapeutics, Inc.(NasdaqGS: STOK) dropped from Russell Microcap Index
Stoke Therapeutics, Inc. (NasdaqGS: STOK) has been removed from the Russell Microcap Index. The biotechnology company focuses on developing RNA-based medicines to treat severe diseases by upregulating protein expression, with its lead compound zorevunersen in clinical trials for Dravet syndrome and autosomal dominant optic atrophy. The article also provides recent news and financial data for the company.
Does Broad Russell Index Removal Reshape the Bull Case for Stoke Therapeutics (STOK)?
Stoke Therapeutics (STOK) was removed from several Russell indices, including the Russell Microcap and Russell 3000E, on June 27, 2026. This removal is expected to alter the company's investor base and trading patterns, potentially impacting its investment narrative and risk profile. Despite the index changes, the company's core investment case still hinges on the success of its drug zorevunersen in Phase III trials, with analysts holding diverse views on its future performance.
Assenagon Asset Management S.A. Sells 320,708 Shares of Stoke Therapeutics, Inc. $STOK
Assenagon Asset Management S.A. reduced its stake in Stoke Therapeutics (NASDAQ:STOK) by 26.1% in the first quarter, selling 320,708 shares and retaining 907,015 shares valued at $29.5 million. Despite insider selling by General Counsel Jonathan Allan and insider Barry Ticho, analysts maintain a "Moderate Buy" consensus rating with a target price of $41.83. Other institutional investors like Vanguard Group and Baillie Gifford & Co. either increased or initiated positions in the company.
Price to sales forward of Stoke Therapeutics, Inc. – NASDAQ:STOK
This article displays the "Price to sales forward" metric for Stoke Therapeutics, Inc. (NASDAQ: STOK) on the TradingView platform. It shows the current value, change, and percentage change for this financial indicator. The content is primarily a data display with minimal descriptive text.
Enterprise value to revenue forward of Stoke Therapeutics, Inc. – NASDAQ:STOK
This article focuses solely on the "Enterprise value to revenue forward" financial metric for Stoke Therapeutics, Inc. (NASDAQ:STOK). The content provided is a direct display of this financial data point from TradingView, indicating a specific period, its value, and the percentage change. The article itself does not offer any further analysis or descriptive text beyond presenting this single financial datum.
Price to book forward of Stoke Therapeutics, Inc. – NASDAQ:STOK
This page displays the "Price to book forward" financial metric for Stoke Therapeutics, Inc. (NASDAQ: STOK). It is presented within the context of TradingView's financial data offerings for stocks in the health technology and biotechnology sectors. The article indicates that this specific metric is "Made by humans."
Stoke Therapeutics (STOK) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary
Stoke Therapeutics (STOK) presented at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026, highlighting significant progress in its clinical trials for Dravet syndrome and ADOA. The company reported up to 80% seizure reduction and cognitive improvements in Dravet syndrome patients, with Phase 3 enrollment expected to complete in Q2 2026 and data readout by mid-2027. Stoke also mentioned its strong financial position with a cash runway into 2028 and ongoing pipeline development.
Understanding the Setup: (STOK) and Scalable Risk
This article analyzes Stoke Therapeutics Inc. (NASDAQ: STOK), identifying positive near-term sentiment within a long-term strength context, while noting an elevated downside risk in the absence of clear long-term support signals. It provides AI-generated signals for STOK, including specific entry and exit points for various trading strategies like position trading, momentum breakout, and risk hedging, alongside multi-timeframe signal analysis. The piece also highlights the predictive AI's ability to offer real-time signals and risk parameters for institutional trading strategies.
Stoke Therapeutics general counsel sells $43,637 in common stock
Jonathan Allan, General Counsel & Corporate Secretary at Stoke Therapeutics (NASDAQ:STOK), recently sold 1,457 shares of the company's common stock for a total of $43,637. The transaction, on June 16, 2026, was executed under a Rule 10b5-1 trading plan adopted in November 2025. This sale occurred despite the stock gaining 162% over the past year, while InvestingPro analysis suggests the stock is currently overvalued.
Insider Sell Alert: Jonathan Allan Sells Shares of Stoke Therapeutics Inc (STOK)
Jonathan Allan, General Counsel & Corporate Secretary at Stoke Therapeutics Inc (STOK), sold 1,457 shares of the company on June 16, 2026. This transaction follows a pattern of insider selling over the past year, with no insider buys recorded. Shares of STOK are trading at $29.95, significantly above its GF Value of $10.18, suggesting the stock is overvalued.
Stoke Therapeutics (STOK) legal chief sells 1,457 shares under 10b5-1 plan
Jonathan Allan, General Counsel and Corporate Secretary of Stoke Therapeutics (STOK), sold 1,457 shares of Common Stock at $29.95 per share on June 16, 2026. This transaction was conducted under a pre-established Rule 10b5-1 trading plan adopted on November 10, 2025, meaning it was a pre-arranged sale and not a discretionary market-timing decision. Following the sale, Allan directly holds 18,086 shares of the company's Common Stock.
Stoke Therapeutics Inc (STOK) Institutional Confidence
Stoke Therapeutics Inc (STOK) has an institutional shareholding score of 10.00, placing it first in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 118.29%, showing a slight quarter-over-quarter decrease. John Hussman is the largest institutional shareholder, holding 0.13% of outstanding shares.
Stoke Therapeutics Inc (STOK) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Stoke Therapeutics Inc (STOK) stock, focusing on its dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years and has no record of stock splits. The page also presents current stock price information, market capitalization, and links to other financial data and analysis for STOK.
Granahan Investment Management LLC Has $6.08 Million Stock Position in Stoke Therapeutics, Inc. $STOK
Granahan Investment Management LLC reduced its stake in Stoke Therapeutics (NASDAQ:STOK) by 24.6% in the fourth quarter, now holding 191,397 shares valued at $6.08 million. Despite this, other institutional investors like Morgan Stanley, Vanguard Group Inc., State Street Corp, Goldman Sachs Group Inc., and Polar Capital Holdings Plc increased their positions in the company. Stoke Therapeutics reported earnings that topped consensus estimates, although revenue slightly missed predictions, and the company has an average analyst rating of "Moderate Buy" with an average price target of $41.83.
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - June 16, 2026
Stoke Therapeutics announced that on June 15, 2026, it granted stock options to nine new employees as an inducement to their employment, in accordance with Nasdaq Listing Rule 5635(c)(4). These options cover 103,020 shares of common stock, with an exercise price matching the closing price of Stoke's common stock on June 15, 2026, which was $30.00 per share. The options will vest over a four-year period, tied to continued employment.
Insider sales at STOK (NASDAQ: STOK) list 27,481 shares in March 2026
A Form 144 filing by Morgan Stanley Smith Barney LLC Executive Financial Services disclosed insider sales by Jonathan Allan of Stoke Therapeutics (NASDAQ: STOK) under a 10b5-1 plan. The filing details dispositions of 27,481 shares across multiple transactions in March 2026, with specific share counts and gross sale amounts per date. These sales are considered routine planned dispositions rather than new company actions.
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Stoke Therapeutics, Inc. (Nasdaq: STOK) announced it granted stock options for 103,020 shares of common stock to nine new employees on June 15, 2026, as a material inducement to their employment. The options have an exercise price of $30.00 per share, vest over four years, and are granted in accordance with Nasdaq Listing Rule 5635(c)(4). Stoke Therapeutics is a biotechnology company focused on RNA medicine, with zorevunersen in development for Dravet syndrome.
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Rating of "Moderate Buy" from Analysts
Stoke Therapeutics, Inc. (NASDAQ:STOK) has received a "Moderate Buy" rating from analysts, with nine out of eleven rating it a buy. The average one-year price target is $41.83. Despite recent insider selling and a slight revenue miss, the company beat EPS expectations for the last quarter.
Rhenman & Partners Asset Management AB Lowers Position in Stoke Therapeutics, Inc. $STOK
Rhenman & Partners Asset Management AB has decreased its stake in Stoke Therapeutics (NASDAQ:STOK) by 13.6% in the fourth quarter, reducing its holdings to 216,000 shares worth approximately $6.86 million. This comes alongside recent insider selling activity, with Barry Ticho and Jason Hoitt selling shares in March. Despite the reduction in institutional holdings and insider selling, Stoke Therapeutics surpassed earnings estimates, and analysts maintain a "Moderate Buy" rating with an average target price of $41.83.
Stoke Therapeutics (NASDAQ:STOK) Trading Up 1.6% - Should You Buy?
Stoke Therapeutics (NASDAQ:STOK) saw its shares climb 1.6% in Friday trading, closing at $29.82, though analysts have mixed ratings on the stock. While nine analysts rate it a “Buy” with a consensus “Moderate Buy” rating and an average target price of $41.83, Weiss Ratings recently downgraded it to “Sell.” The company reported a smaller-than-expected quarterly loss but revenue missed estimates, and insiders, including the general counsel, have been selling shares.
Stoke Therapeutics (STOK) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary
Stoke Therapeutics presented at the Goldman Sachs 47th Annual Global Healthcare Conference, highlighting significant progress in developing zorevunersen for Dravet syndrome. The company discussed durable efficacy data from its open-label extension study, showing a 75% seizure reduction and cognitive improvements. They also outlined plans for a rolling NDA submission starting in Q1 2027, with an anticipated U.S. launch in late 2027 or early 2028.
STOK: Durable efficacy and cognitive gains position zorevunersen for a focused U.S. launch by 2028
Stoke Therapeutics (STOK) is preparing for a focused U.S. launch of zorevunersen by 2028, targeting 6,000 patients with Dravet syndrome. The drug has shown durable seizure reduction and cognitive gains, with Phase III trials nearing full enrollment and a rolling NDA submission planned for 2027. The company's leadership is emphasizing advocacy and organizational build-out, supported by strong financials and a Biogen partnership for global expansion.
The Technical Signals Behind (STOK) That Institutions Follow
This article provides a technical analysis of Stoke Therapeutics Inc. (NASDAQ: STOK), highlighting weak near-term sentiment but strong long-term support signals. It outlines institutional trading strategies including long, breakout, and short positions, along with multi-timeframe signal analysis for varying horizons. The analysis emphasizes AI-generated signals for entry, target, and stop-loss levels, cautioning about choppy conditions due to divergent sentiments across different timeframes.
Assessing Stoke Therapeutics (STOK) Valuation After Recent Share Price Cooling
Stoke Therapeutics (STOK) has seen its share price cool recently, dropping 10-15% over the past one to three months, despite a strong performance over the last year. Currently trading at US$30.01 with a market cap of US$1.88 billion, analysts suggest the stock is undervalued, with a fair value of $34.25. The company's valuation hinges on its TANGO platform and pipeline for genetic diseases, with future performance dependent on Phase 3 results and regulatory decisions.
Stoke Therapeutics (STOK) director receives grant of 17,786 stock options
Stoke Therapeutics (STOK) director Arthur Tzianabos was granted 17,786 stock options with an exercise price of $29.46 per share. These options expire on June 2, 2036, and will vest in full on the earlier of June 3, 2027, or the company’s next annual stockholder meeting, contingent on his continued service. This insider transaction was reported as a neutral event by Rhea-AI.
[Form 4] Stoke Therapeutics, Inc. Insider Trading Activity
Stoke Therapeutics director Julie Smith was granted 17,786 stock options on June 3, 2026, with an exercise price of $29.46 per share. These options will vest fully by June 3, 2027, or the next annual shareholder meeting, contingent on her continued service. The options are set to expire on June 2, 2036.
Stoke Therapeutics (STOK) director awarded 17,786 options at $29.46 strike
Stoke Therapeutics director Adrian R. Krainer was granted 17,786 stock options to purchase common shares at an exercise price of $29.46 each. These options serve as compensation and will fully vest on the earlier of June 3, 2027, or the company’s next annual stockholder meeting, provided Krainer continues his service. Following this grant, Krainer holds 17,786 options which are set to expire on June 2, 2036.
Stoke Therapeutics (NASDAQ: STOK) 2026 meeting elects all directors
Stoke Therapeutics Inc. (NASDAQ: STOK) announced the results of its 2026 Annual Meeting of Stockholders held on June 3, 2026. Shareholders elected G. Clare Kahn, Ph.D., Adrian Krainer, Ph.D., and Julie Anne Smith as directors, each for a three-year term. Additionally, stockholders approved the ratification of Ernst & Young LLP as the company's independent registered public accounting firm for fiscal year 2026 and approved, on a non-binding advisory basis, the compensation of named executive officers.
Stoke Therapeutics (STOK) CMO sells 1,795 shares under 10b5-1 plan
Stoke Therapeutics (STOK) Chief Medical Officer Barry Ticho sold 1,795 shares of common stock at $30.58 per share, a transaction reported on a Form 4 filing. This sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 19, 2025. After the transaction, Ticho holds 34,826 shares of company stock.
Insider Sell Alert: Barry Ticho Sells Shares of Stoke Therapeuti
Barry Ticho, Chief Medical Officer of Stoke Therapeutics Inc (STOK), sold 1,795 shares on June 1, 2026, reducing his holdings to 34,826 shares. This transaction follows a pattern of 37 insider sells and no buys for STOK over the past year. The stock is currently trading at $30.58, which is significantly overvalued compared to its GF Value of $10.22.
The Bull Case For Stoke Therapeutics (STOK) Could Change Following Long-Term Zorevunersen Data And Phase 3 Plans
Stoke Therapeutics recently provided long-term Phase 1/2a data for zorevunersen, showing sustained cognitive, behavioral, and seizure improvements over five years, with the therapy remaining well-tolerated. The company also detailed its late-stage development plans, aiming to complete enrollment for the Phase 3 EMPEROR trial by June 2026, with data expected mid-2027 and a rolling US NDA submission in Q1 2027. This update strengthens the investment case for Stoke, focusing attention on the mid-2027 data as a key inflection point, while acknowledging the risks associated with the Phase 3 trial outcomes and potential regulatory delays.
The Bull Case For Stoke Therapeutics (STOK) Could Change Following Long-Term Zorevunersen Data And Phase 3 Plans
Stoke Therapeutics (STOK) reported positive four-year Phase 1/2a data for zorevunersen, showing sustained improvements in Dravet syndrome, and outlined plans for a Phase 3 trial (EMPEROR) with enrollment completion targeted by June 2026 to support a mid-2027 data release. This progress strengthens the investment case by clarifying timelines and reinforcing the therapy's long-term safety and efficacy profile, though risks remain regarding Phase 3 outcomes and regulatory approvals. The company anticipates an $81.1 million revenue by 2028 and a fair value of $34.25, suggesting a potential 12% upside.
Stoke Therapeutics, Inc. (STOK) Reports Q1 Results and Business Updates
Stoke Therapeutics, Inc. (STOK) reported its Q1 results, highlighting positive four-year data from Phase 1/2a studies for "Zorevunersen" in Dravet syndrome, showing significant gains in cognition and behavior, and seizure reduction. The company expects to complete enrollment for the Phase 3 EMPEROR study by June 2026, targeting a mid-2027 data release and Q1 2027 NDA submission. With $411 million in cash and investments as of March 31, 2026, Stoke Therapeutics is funded into 2028.
Stoke Therapeutics to Present at Upcoming Investor Conferences in June
Stoke Therapeutics announced that its CEO and Chief Patient Officer will present at two investor conferences in June 2026: the Jefferies Global Healthcare Conference and the Goldman Sachs 47th Annual Global Healthcare Conference. The company, which focuses on RNA medicine and has a lead investigational medicine zorevunersen for Dravet syndrome, will make webcasts of these presentations available on its investor relations website.
Stoke Therapeutics to Present at Upcoming Investor Conferences in June
Stoke Therapeutics, Inc. announced that its CEO Ian F. Smith and Chief Patient Officer Jason Hoitt will present at two upcoming investor conferences in June 2026: the Jefferies Global Healthcare Conference and the Goldman Sachs 47th Annual Global Healthcare Conference. The company, focused on RNA medicine for conditions like Dravet syndrome, will make live webcasts and archived replays of these presentations available on its investor relations website.
Stoke Therapeutics (Nasdaq:STOK) - Stock Analysis
Stoke Therapeutics (STOK) is a biotechnology company focused on treatments for severe genetic diseases, with a lead candidate, zorevunersen, for Dravet syndrome currently in Phase 3 trials. The company reported a net loss of $50 million in Q1 2026, though revenue exceeded analyst estimates. Despite stock volatility and insider selling, promising long-term data for zorevunersen, its cash runway into 2028, and a broad RNA medicine pipeline show potential.
Precision Trading with Stoke Therapeutics Inc. (STOK) Risk Zones
This article by Stock Traders Daily's Quantitative Research Desk analyzes Stoke Therapeutics Inc. (STOK), indicating positive near-term sentiment but a weak mid-term bias within a long-term strength context. It identifies elevated downside risk and provides three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and holding periods, complete with entry zones, targets, and stop losses. The analysis also includes a multi-timeframe signal breakdown for near-term, mid-term, and long-term horizons, outlining support and resistance levels.
UBS Group AG Decreases Stock Position in Stoke Therapeutics, Inc. $STOK
UBS Group AG significantly reduced its stake in Stoke Therapeutics (NASDAQ:STOK) by 44.5% in the fourth quarter, now holding 169,713 shares valued at $5.39 million. This adjustment follows mixed financial results from Stoke Therapeutics, which reported a narrower-than-expected quarterly loss but missed revenue forecasts. Despite this, Wall Street analysts maintain a "Moderate Buy" rating for STOK, with a consensus price target of $41.83, indicating cautious optimism for the stock's future.
Is it a Good Idea to Invest in Stoke Therapeutics Stock Now?
Stoke Therapeutics (STOK) is advancing its lead candidate, zorevunersen, for Dravet syndrome, which has received Breakthrough Therapy designation from the FDA. The company's shares have significantly outperformed the industry, and it has a strategic collaboration with Biogen. With strong cash reserves and positive Zacks Rank, the article suggests Stoke Therapeutics is a good investment, also highlighting other top-ranked biotech stocks.
Stoke Therapeutics (STOK) Is Down 7.8% After Sharp Q1 Swing From Profit To Loss – What's Changed
Stoke Therapeutics (STOK) experienced a significant financial shift in Q1 2026, swinging from a net profit to a US$50 million net loss, with sales dropping to US$6.23 million. This change is primarily attributed to increased spending on its EMPEROR Phase III program and preparations for commercialization of zorevunersen, rather than a fundamental change in its pipeline prospects. Despite the short-term volatility and financial setback, the company's investment narrative remains centered on the success of its RNA platform and the upcoming regulatory milestones for its Dravet syndrome treatment.
Stoke Therapeutics (STOK) Is Down 7.8% After Sharp Q1 Swing From Profit To Loss – What's Changed
Stoke Therapeutics (STOK) experienced a significant financial shift in Q1 2026, moving from a net profit to a US$50 million net loss, with sales of US$6.23 million. This change is primarily linked to increased spending on advancing its EMPEROR Phase III program and preparing for potential commercialization of zorevunersen. Despite the near-term volatility, the company's investment narrative still hinges on the success of its RNA platform and upcoming regulatory milestones, with analysts predicting future revenue and earnings decreases but a fair value implying an upside.
Zorevunersen tied to long-term benefits in Dravet syndrome
Four-year data from long-term extension studies (SWALLOWTAIL and LONGWING) for Stoke Therapeutics' zorevunersen show sustained seizure reductions and cognitive and behavioral improvements in patients with Dravet syndrome. The investigational therapy, designed to increase functional NaV1.1 production, was generally well tolerated. Enrollment for the global Phase 3 EMPEROR trial is expected to complete in June, with data anticipated in mid-2027 to support a U.S. regulatory submission.
